Assessing the impact of protocol design changes on clinical trial performance.
about
User Satisfaction Evaluation of the EHR4CR Query Builder: A Multisite Patient Count Cohort System.Key cost drivers of pharmaceutical clinical trials in the United StatesA National Cancer Clinical Trials Network: recommendations from the Institute of MedicineIncreasing value and reducing waste in biomedical research regulation and managementStock market returns and clinical trial results of investigational compounds: an event study analysis of large biopharmaceutical companiesClinical trials from the patient perspective: survey in an online patient community.Improving protocol design feasibility to drive drug development economics and performanceAccrual and recruitment practices at Clinical and Translational Science Award (CTSA) institutions: a call for expectations, expertise, and evaluation.Trends in risks associated with new drug development: success rates for investigational drugs.A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT).Evaluating protocol lifecycle time intervals in HIV/AIDS clinical trials.Deconstructing the drug development process: the new face of innovationDistance from home to study clinic and risk of follow-up interruption in a cohort of HIV-1-discordant couples in Nairobi, Kenya.Five-step authorship framework to improve transparency in disclosing contributors to industry-sponsored clinical trial publicationsClinical trials in crisis: Four simple methodologic fixes.Ontario protocol assessment level: clinical trial complexity rating tool for workload planning in oncology clinical trials.Why do we pay? A national survey of investigators and IRB chairpersons.Relation of study design to recruitment and retention in CTN trials.Efficiency and effectiveness evaluation of an automated multi-country patient count cohort systemAccrual Index: A Real-Time Measure of the Timeliness of Clinical Study Enrollment.Activating clinical trials: a process improvement approachIntraarterial Microdosing: A Novel Drug Development Approach, Proof-of-Concept PET Study in Rats.Protocol Development Program: A Novel Approach to Overcoming Barriers to Clinical Research.Upholding the principles of autonomy, beneficence, and justice in phase I clinical trials.CNS sites cooperate to detect duplicate subjects with a clinical trial subject registry.Measuring clinical trial-associated workload in a community clinical oncology programOptimization of protocol design: a path to efficient, lower cost clinical trial execution.Bridging the gap: improving clinical development and the regulatory pathways for health products for neglected diseases.The Burden of the "False-Negatives" in Clinical Development: Analyses of Current and Alternative Scenarios and Corrective Measures.Intra-Target Microdosing - A Novel Drug Development Approach: Proof of Concept, Safety, and Feasibility Study in Humans.Patient enrollment onto clinical trials: the role of physician knowledge.Impediments to clinical research in the United States.How many research nurses for how many clinical trials in an oncology setting? Definition of the Nursing Time Required by Clinical Trial-Assessment Tool (NTRCT-AT).Increasing protocol suitability for clinical trials in sub-Saharan Africa: a mixed methods study.Pharmaceutical new product development: why do clinical trials fail?
P2860
Q27314928-BFEA554A-E037-4640-8423-6A5B3692BDF4Q28273573-B5958DD4-0412-47D9-BAD4-ED387CA3DE35Q28305510-C2CBA606-7E8A-4880-988E-3FCBA309B92EQ28657841-9E0C39AE-4DD7-4DF9-942F-0C9BB3BE558CQ28686746-AD009811-71AA-48AC-9A4F-832046185AB7Q30839990-C51B97D1-55B4-4247-9C86-5F77130DC7EDQ33742219-2FED2100-18EC-464B-94A0-637ACB462BBAQ33976642-FD6DF8D0-AA94-4897-B7B8-868AE17EF98EQ34096792-6F693882-9D05-4FCD-AE27-6EF7A6052B6BQ34142018-4BBEFFC6-E98D-4874-B9BE-83F497988D75Q34145349-5DAC4805-C53C-4852-9864-1B81C9FC81D4Q34190877-0FDD921A-B835-4804-A6E5-97EACD021D79Q34398967-1E315249-F682-4399-BDA0-1E6AF6607A24Q34402190-28649451-7D43-4EEE-9EAC-C47E0416A857Q34498710-8BB891CF-1196-4A05-8E78-7837F79721EFQ34638047-2C57973A-FB1C-435E-B854-B88B3AE0273BQ35200966-427E46F0-3E54-48D9-8E18-0D9124BF8BFCQ35215651-2372F519-83E9-49EF-B807-1A241F446BE0Q35619216-0D672021-01C9-4FF4-944F-3A35F5C2BB20Q36436768-9D1BCA70-99A5-4355-84CC-CC2497FEF429Q36611986-D72C1316-0ED9-45C7-8E10-42774DEB9051Q36618309-32571504-C780-4DC6-BFE2-226DC0BB39C5Q36709739-1F360D0A-50A4-40B1-81AE-6FBE4B6F6743Q36714355-BB812C10-F726-48E3-A7C8-92003F2EB303Q36737423-6648BF3A-C4DF-42F3-8E63-4878AAB70686Q37008529-B318BB37-C056-4AE9-906E-602F6608BE9AQ37474388-B13EDFD5-BE4E-4B2F-9084-84BEF0D6D93CQ37812534-698B6179-E09B-44B2-8800-B747E852AD83Q40135662-CDEB680A-27C4-4D28-AF32-1AE0147530C9Q41369567-B55299B8-2AD4-436D-B1D3-30FE5A623463Q43770725-6A17D19D-B735-4A36-90D2-9399C03C2A4CQ48485541-4D05D39C-4658-4D97-A4F2-1C98B6F0B139Q51024590-802FBD7F-C3B9-4F45-ACC2-A96F4AD3F6F5Q53711068-697E9EF3-D1AF-432A-8196-FBA561C36A60Q54956147-87B35033-EF8E-486E-8799-5E4117B46738
P2860
Assessing the impact of protocol design changes on clinical trial performance.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Assessing the impact of protocol design changes on clinical trial performance.
@en
Assessing the impact of protocol design changes on clinical trial performance.
@nl
type
label
Assessing the impact of protocol design changes on clinical trial performance.
@en
Assessing the impact of protocol design changes on clinical trial performance.
@nl
prefLabel
Assessing the impact of protocol design changes on clinical trial performance.
@en
Assessing the impact of protocol design changes on clinical trial performance.
@nl
P2093
P1476
Assessing the impact of protocol design changes on clinical trial performance.
@en
P2093
Edward S Seguine
Julia Wenger
Kenneth A Getz
Kenneth I Kaitin
Rafael A Campo
P304
P356
10.1097/MJT.0B013E31816B9027
P577
2008-09-01T00:00:00Z